Eli Lilly partner AbCellera finds a CBO in the face of bamlanivimab struggles; FibroGen's next CSO walks into roxadustat rebuff
→ Covid-19 variants have marred the effectiveness of Eli Lilly and AbCellera’s bamlanivimab to such an extent that the US government stopped using the monoclonal antibody in March, followed by a similar halt for the combo treatment with etesevimab late last month. AbCellera is nonetheless pressing onward with a new candidate for mild to moderate cases, LY-CoV1404, and this week Neil Berkley joined Carl Hansen’s squad as CBO. Berkley, a GlaxoSmithKline neuroscience veteran, makes the leap from Halozyme, starting out at the San Diego biotech as head of oncology global partnering, corporate development in 2019 and earning a promotion to VP, head of business development.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.